Empagliflozin reduces extracellular volume and myocardial sodium content in patients with heart failure and preserved ejection fraction and correlates with reverse cardiac remodeling (EMPAG CMR-HF)

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Insights in cardiac magnetic resonance heart failure imaging Extracellular Volume ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by